Farmacore Biotechnology Ltd

farmacore.com.be

Farmcore is a biotech company that develops and improves value in innovative biotechnological products during all stages, since conception of projects, to supply of active pharmaceutical ingredients (immunobiologicals) specially for the veterinary sector. As a Contract Manufacturing Organization, Farmcore owns technologically advanced Bioprocess Facilities allowing the production of a wide range of plasmid needs, permitting the lowest cost of production and highest product quality, especially in GMP regulated environments.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

news image

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More

Cell and Gene Therapy

GAMMA BIOSCIENCES AND LONZA COLLABORATE TO CO-DEVELOP REAGENTS FOR CLINICAL CELL SELECTION IN THE COCOON® PLATFORM

Gamma Biosciences | October 13, 2022

news image

Gamma Biosciences, a leading provider of tools and technologies for cell and gene therapy manufacturing, through their BioMagnetic Solutions business announced a strategic collaboration with Lonza. Under the multi-year agreement, BioMagnetic Solutions will supply its proprietary research and cGMP manufacturing grade FerroSelect™ reagents to Lonza for use in developing CAR-T and other immunotherapeutic products using Lonza's Cocoon® Platform. " Read More

CURIS ANNOUNCES $30 MILLION COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC

BioSpace | February 27, 2020

news image

Curis, Inc. a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock purchase agreement (the "Agreement") of up to $30 million with Aspire Capital Fund, LLC ("Aspire Capital"). Under the terms of the Agreement, Aspire Capital has made an initial investment of $3 million via purchase of 2,693,965 common shares of Curis. In addition, Aspire Capital has committed to purchasi...

Read More

CELLECT BIOTECHNOLOGY ANNOUNCES POSITIVE DATA DEMONSTRATING ROBUST ENGRAFTMENT USING APOGRAFT WAS FEATURED IN BONE MARROW TRANSPLANTATION

PR Newswire | May 11, 2020

news image

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced the publication of an article in Bone Marrow Transplantation, a peer-reviewed medical journal )member of the Nature publishing house) covering transplantation of bone marrow in humans and published monthly by the prestigious Nature Research, entitled 'Ex-vivo FAS-ligand to Improve Allograft Safety'. The article is co-authored by researchers...

Read More
news image

Industrial Impact

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More
news image

Cell and Gene Therapy

GAMMA BIOSCIENCES AND LONZA COLLABORATE TO CO-DEVELOP REAGENTS FOR CLINICAL CELL SELECTION IN THE COCOON® PLATFORM

Gamma Biosciences | October 13, 2022

Gamma Biosciences, a leading provider of tools and technologies for cell and gene therapy manufacturing, through their BioMagnetic Solutions business announced a strategic collaboration with Lonza. Under the multi-year agreement, BioMagnetic Solutions will supply its proprietary research and cGMP manufacturing grade FerroSelect™ reagents to Lonza for use in developing CAR-T and other immunotherapeutic products using Lonza's Cocoon® Platform. " Read More

news image

CURIS ANNOUNCES $30 MILLION COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC

BioSpace | February 27, 2020

Curis, Inc. a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock purchase agreement (the "Agreement") of up to $30 million with Aspire Capital Fund, LLC ("Aspire Capital"). Under the terms of the Agreement, Aspire Capital has made an initial investment of $3 million via purchase of 2,693,965 common shares of Curis. In addition, Aspire Capital has committed to purchasi...

Read More
news image

CELLECT BIOTECHNOLOGY ANNOUNCES POSITIVE DATA DEMONSTRATING ROBUST ENGRAFTMENT USING APOGRAFT WAS FEATURED IN BONE MARROW TRANSPLANTATION

PR Newswire | May 11, 2020

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced the publication of an article in Bone Marrow Transplantation, a peer-reviewed medical journal )member of the Nature publishing house) covering transplantation of bone marrow in humans and published monthly by the prestigious Nature Research, entitled 'Ex-vivo FAS-ligand to Improve Allograft Safety'. The article is co-authored by researchers...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us